FDA approves first twice-yearly injection that prevents HIV infection

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly changeable — the archetypal and lone of its benignant — to prevent HIV, the creator of the drug, Gilead Sciences, announced connected Wednesday.

Sold nether the sanction Yeztugo, the company’s injectable HIV-1 capsid inhibitor (lenacapavir) reduces the hazard of sexually acquired HIV successful adults and adolescents.

"This is simply a historical time successful the decades-long combat against HIV," said Daniel O’Day, president and CEO of California-based Gilead Sciences, successful a property release.

ALZHEIMER'S DISEASE COULD BE PREVENTED BY ANTIVIRAL DRUG ALREADY ON MARKET

The medicine, which lone needs to beryllium administered doubly a year, has shown "remarkable outcomes successful clinical studies," arsenic Gilead claims it could alteration HIV prevention.

The U.S. Food and Drug Administration has approved a new, twice-yearly shot, Yeztugo, to forestall HIV, the creator of the cause announced connected Wednesday. (Gilead Sciences via AP)

The cause is fixed arsenic an injectable nether the tegument that the assemblage past dilatory absorbs. Individuals indispensable person a antagonistic HIV-1 trial anterior to starting the treatment.

CLICK HERE TO GET THE FOX NEWS APP

In ample trials past year, the cause was not lone astir 100% effectual successful its prevention of HIV, but proved superior to once-daily oral medicine similar Truvada, different cause by Gilead.

The cause is fixed arsenic an injectable nether the tegument that the assemblage past dilatory absorbs. Individuals indispensable person a antagonistic HIV-1 trial anterior to starting the treatment. (AP Photo/Nardus Engelbrecht)

The diary Science named lenacapavir its 2024 "Breakthrough of the Year."

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Lenacapavir uses a multi-stage attack that distinguishes it from different approved antiviral medications. 

Sold nether the sanction Yeztugo, the company’s injectable HIV-1 capsid inhibitor (lenacapavir) reduces the hazard of sexually acquired HIV successful adults and adolescents. (iStock)

"While astir antivirals enactment connected conscionable 1 signifier of viral replication, lenacapavir is designed to inhibit HIV astatine aggregate stages of its lifecycle," states the property merchandise from Gilead.

For much Health articles, visit www.foxnews.com/health

"Yeztugo is 1 of the astir important technological breakthroughs of our clip and offers a precise existent accidental to assistance extremity the HIV epidemic," O’Day said successful the property release.

The astir commonly reported adverse reactions during objective trials included injection tract reactions, headache and nausea, according to the company.